Dainippon Sumitomo Pharma Biomedical To Market Serum Free STK2
This article was originally published in PharmAsia News
Executive Summary
Dainippon Sumitomo Pharma's biopharma subsidiary, Hiroshima-based DS Pharma Biomedical will market STK2, a human mesenchymal stem cell made by serum-free culture media on May 12. The company obtained the serum-free media technology from Twocell, a Japanese regenerative medicine venture company also based in Hiroshima. Currently, fetal bovine serum or human serum is needed to culture human mesenchymal stem cells. The company comments that the product will contribute greatly to the regenerative medicine area. (Click here for more - Japanese language)